Bayesian hierarchical models for adaptive basket trial designs.

Chian Chen, Chin-Fu Hsiao
Author Information
  1. Chian Chen: Institute of Population Health Sciences, National Health Research Institutes, Miaoli County, Taiwan. ORCID
  2. Chin-Fu Hsiao: Institute of Population Health Sciences, National Health Research Institutes, Miaoli County, Taiwan. ORCID

Abstract

Basket trials evaluate a single drug targeting a single genetic variant in multiple cancer cohorts. Empirical findings suggest that treatment efficacy across baskets may be heterogeneous. Most modern basket trial designs use Bayesian methods. These methods require the prior specification of at least one parameter that permits information sharing across baskets. In this study, we provide recommendations for selecting a prior for scale parameters for adaptive basket trials by using Bayesian hierarchical modeling. Heterogeneity among baskets attracts much attention in basket trial research, and substantial heterogeneity challenges the basic assumption of exchangeability of Bayesian hierarchical approach. Thus, we also allowed each stratum-specific parameter to be exchangeable or nonexchangeable with similar strata by using data observed in an interim analysis. Through a simulation study, we evaluated the overall performance of our design based on statistical power and type I error rates. Our research contributes to the understanding of the properties of Bayesian basket trial designs.

Keywords

References

  1. Heinrich MC, Joensuu H, Demetri GD, et al. Phase II, open-label study evaluating the activity of imatinib in treating life-threatening malignancies known to be associated with imatinib-sensitive tyrosine kinases. Clin Cancer Res. 2008;14:2717-2725.
  2. Hyman DM, Puzanov I, Subbiah V, et al. Vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutations. N Engl J Med. 2015;373:726-736.
  3. Chu YY, Yuan Y. A Bayesian basket trial design using a calibrated Bayesian hierarchical model. Clin Trials. 2018;15:149-158.
  4. Chenard-Poirier M, Kaiser M, Boyd K, et al. Results from the biomarker-driven basket trial of RO5126766 (CH5127566), a potent RAF/MEK inhibitor, in RAS- or RAF-mutated malignancies including multiple myeloma. J Clin Oncol. 2017;35:2506.
  5. Hainsworth JD, Meric-Bernstam F, Swanton C, et al. Targeted therapy for advanced solid tumors on the basis of molecular profiles: results from mypathway, an open-label, phase IIa multiple basket study. J Clin Oncol. 2018;36:536-542.
  6. Li BT, Shen RL, Buonocore D, et al. Ado-Trastuzumab Emtansine for patients with HER2-mutant lung cancers: results from a phase II basket trial. J Clin Oncol. 2018;36:2532-2537.
  7. Simon R. New designs for basket clinical trials in oncology. J Biopharm Stat. 2018;28(2):245-255.
  8. Thall PF, Wathen JK, Bekele BN, Champlin RE, Baker LH, Benjamin RS. Hierarchical Bayesian approaches to phase II trials in diseases with multiple subtypes. Stat Med. 2003;22:763-780.
  9. Berry SM, Broglio KR, Groshen S, Berry DA. Bayesian hierarchical modeling of patient subpopulations: efficient designs of phase II oncology clinical trials. Clin Trials. 2013;10:720-734.
  10. Freidlin B, Korn EL. Borrowing information across subgroups in phase II trials: is it useful? Clin Cancer Res. 2013;19:1326-1334.
  11. Burke DL, Bujkiewicz S, Riley RD. Bayesian bivariate meta-analysis of correlated effects: impact of the prior distributions on the between-study correlation, borrowing of strength, and joint inferences. Stat Methods Med Res. 2018;27:428-450.
  12. Gelman A. Prior distributions for variance parameters in hierarchical models (comment on an article by Browne and Draper). Bayes Anal. 2006;1:515-533.
  13. Lambert PC, Sutton AJ, Burton PR, Abrams KR, Jones DR. How vague is vague? A simulation study of the impact of the use of vague prior distributions in MCMC using WinBUGS. Stat Med. 2005;24:2401-2428.
  14. Cunanan KM, Iasonos A, Shen RL, Gonen M. Variance prior specification for a basket trial design using Bayesian hierarchical modeling. Clin Trials. 2019;16:142-153.
  15. Lin R, Thall PF, Yuan Y. A phase I-II basket trial design to optimize dose-schedule regimes based on delayed outcomes. Bayes Anal. 2020;16:179-202.
  16. Jin J, Riviere MK, Luo XD, Dong YW. Bayesian methods for the analysis of early-phase oncology basket trials with information borrowing across cancer types. Stat Med. 2020;39:3459-3475.
  17. Hobbs BP, Landin R. Bayesian basket trial design with exchangeability monitoring. Stat Med. 2018;37(25):3557-3572.
  18. Kaizer AM, Koopmeiners JS, Hobbs BP. Bayesian hierarchical modeling based on multisource exchangeability. Biostatistics. 2018;19(2):169-184.
  19. Kane MJ, Chen N, Kaizer AM, Jiang X, Xia HA, Hobbs BP. Analyzing basket trials under multisource exchangeability assumptions. R J. 2020;12(2):360-372.
  20. Neuenschwander B, Wandel S, Roychoudhury S, Bailey S. Robust exchangeability designs for early phase clinical trials with multiple strata. Pharm Stat. 2016;15:123-134.
  21. Pohl M, Krisam J, Kieser M. Categories, components, and techniques in a modular construction of basket trials for application and further research. Biom J. 2021;63:1159-1184.
  22. Food & Administration. Interacting with the FDA on Complex Innovative Trial Designs for Drugs and Biological Products: Guidance for Industry. Food & Administration; 2020. https://www.fda.gov/media/130897/download.
  23. Bernardo JM. The concept of exchangeability and its applications. Far East J Math Sci. 1996;4:111-122.
  24. Gelman A, Carlin JB, Stern HS, Dunson DB, Vehtari A, Rubin DB. Bayesian Data Analysis. Taylor & Francis; 2013.
  25. Thall PF, Simon RM, Estey EH. Bayesian sequential monitoring designs for single-arm clinical-trials with multiple outcomes. Stat Med. 1995;14:357-379.
  26. Su YS, Yajima MJR. R2jags: A Package for Running Jags from R. 2012. http://CRAN.R-project.org/package=R2jags.

MeSH Term

Humans
Bayes Theorem
Research Design
Computer Simulation
Neoplasms
Treatment Outcome

Word Cloud

Created with Highcharts 10.0.0basketBayesiantrialhierarchicaltrialsbasketsdesignssingleacrossmethodspriorparameterinformationstudyadaptiveusingresearchdesignBasketevaluatedrugtargetinggeneticvariantmultiplecancercohortsEmpiricalfindingssuggesttreatmentefficacymayheterogeneousmodernuserequirespecificationleastonepermitssharingproviderecommendationsselectingscaleparametersmodelingHeterogeneityamongattractsmuchattentionsubstantialheterogeneitychallengesbasicassumptionexchangeabilityapproachThusalsoallowedstratum-specificexchangeablenonexchangeablesimilarstratadataobservedinterimanalysissimulationevaluatedoverallperformancebasedstatisticalpowertypeerrorratescontributesunderstandingpropertiesmodelsmodelclinicalborrowingprecisionmedicine

Similar Articles

Cited By